Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 20:9:889825.
doi: 10.3389/fmolb.2022.889825. eCollection 2022.

Advances in UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA) Covalent Inhibition

Affiliations
Review

Advances in UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA) Covalent Inhibition

Maycon Vinicius Damasceno de Oliveira et al. Front Mol Biosci. .

Abstract

Peptidoglycan is a cross-linked polymer responsible for maintaining the bacterial cell wall integrity and morphology in Gram-negative and Gram-positive bacteria. The peptidoglycan pathway consists of the enzymatic reactions held in three steps: cytoplasmic, membrane-associated, and periplasmic. The Mur enzymes (MurA-MurF) are involved in a cytoplasmic stage. The UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) enzyme is responsible for transferring the enolpyruvate group from phosphoenolpyruvate (PEP) to UDP-N-acetylglucosamine (UNAG) to form UDP-N-acetylglucosamine enolpyruvate (EP-UNAG). Fosfomycin is a natural product analogous to PEP that acts on the MurA target enzyme via binding covalently to the key cysteine residue in the active site. Similar to fosfomycin, other MurA covalent inhibitors have been described with a warhead in their structure that forms a covalent bond with the molecular target. In MurA, the nucleophilic thiolate of Cys115 is pointed as the main group involved in the warhead binding. Thus, in this minireview, we briefly describe the main recent advances in the design of MurA covalent inhibitors.

Keywords: MurA enzyme; bacterial resistance; covalent inhibitors; fosfomycin; peptidoglycan.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Steps of catalytic reactions performed by the MurA-MurF enzymes in the peptidoglycan biosynthesis.
FIGURE 2
FIGURE 2
Scheme of covalent bond formation in MurA with some examples of warhead covalent inhibitors and the action mechanism of fosfomycin.
FIGURE 3
FIGURE 3
Mechanism for the Michael addition of (A) (ethenesulfonyl)benzene (B) N,N-dimethylprop-2-enamide, and (C) 1-cyclohexyl-2,5-dihydro-1H-pyrrole-2,5-dione against MurA (E. coli).

Similar articles

Cited by

References

    1. Ábrányi-Balogh P., Petri L., Imre T., Szijj P., Scarpino A., Hrast M., et al. (2018). A Road Map for Prioritizing Warheads for Cysteine Targeting Covalent Inhibitors. Eur. J. Med. Chem. 160, 94–107. 10.1016/j.ejmech.2018.10.010 - DOI - PubMed
    1. Aghamali M., Sedighi M., Zahedi bialvaei A., Mohammadzadeh N., Abbasian S., Ghafouri Z., et al. (2019). Fosfomycin: Mechanisms and the Increasing Prevalence of Resistance. J. Med. Microbiol. 68, 11–25. 10.1099/jmm.0.000874 - DOI - PubMed
    1. Araújo J. D. O., Dos Santos A. M., Lameira J., Alves C. N., Lima A. H. (2019). Computational Investigation of Bisphosphate Inhibitors of 3-Deoxy-D-Manno-Octulosonate 8-phosphate Synthase. Molecules 24, 2370. 10.3390/molecules24132370 - DOI - PMC - PubMed
    1. Babiker A., Clarke L., Doi Y., Shields R. K. (2019). Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infection: A Real-World Perspective and Review of the Literature. Diagnostic Microbiol. Infect. Dis. 95, 114856. 10.1016/j.diagmicrobio.2019.06.008 - DOI - PubMed
    1. Bachelier A., Mayer R., Klein C. D. (2006). Sesquiterpene Lactones are Potent and Irreversible Inhibitors of the Antibacterial Target Enzyme MurA. Bioorg. Med. Chem. Lett. 16, 5605–5609. 10.1016/j.bmcl.2006.08.021 - DOI - PubMed